TRC 101Alternative Names: TRC-101
Latest Information Update: 12 Jan 2017
At a glance
- Originator Tricida
- Mechanism of Action Carrier protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Renal failure
Most Recent Events
- 10 Jan 2017 Efficacy and adverse events data from a phase I/II trial in Chronic Kidney Disease released by Tricida
- 10 Jan 2017 Tricida plans a phase III program for chronic kidney disease
- 01 Nov 2016 Tricida completes a phase-I/II clinical trial in Renal failure (In adults, In the elderly) in Georgia and Bulgaria (PO) (NCT02809183)